Cardiovascular disease is a leading cause of morbidity and mortality in type 1 diabetes, yet risk prediction tools tailored for this population remain limited. Presented at the European Association for the Study of Diabetes 2025, new research demonstrates that SCORE2-Diabetes, originally developed for type 2 diabetes, can effectively identify high-risk individuals with type 1 diabetes. 

Data was analysed from 15,514 adults aged 40–69 years without established cardiovascular disease, registered in the Swedish National Diabetes Register between 2006 and 2015. Patients were followed for a mean of 8.8 years to capture major adverse cardiovascular events, including myocardial infarction, ischaemic stroke, or all-cause death. Based on SCORE2-Diabetes, 16% were low risk, 34% moderate, 37% high, and 13% very high risk.

Compared with the low-risk group, hazard ratios for major adverse cardiovascular events increased to 2.2 in moderate-risk, 5.4 in high-risk, and 13.1 in very high-risk individuals (p<0.001). These results highlight a clear gradient in cardiovascular risk, suggesting SCORE2-Diabetes could guide preventive interventions in type 1 diabetes, although further studies are needed to refine risk stratification in this population.